Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

News feed

Zvezda reported for 3 months of 2025 by RAS

5/12/25 ZVEZ

Rosseti North Caucasus reported for 3 months of 2025 by RAS

5/12/25 MRKK

Aeroflot's passenger traffic in April 2025 grew by 6.7%

5/12/25 AFLT

Board of Directors of Zaymer recommended that dividends be paid for 2024

5/12/25 ZAYM

Yandex acquired the platform Domiland

5/12/25 YDEX

MGKL revenue for January-April increased 3.7 times

5/12/25 MGKL

Ozon is gearing up to launch delivery of hot meals

5/12/25 OZON

Alrosa mined the largest gem diamond in the history of Russia

5/8/25 ALRS

RBT will continue to develop the flu and covida vaccine independently

5/7/25 RBTY

Artgen has terminated its agreement with Nacimbio

5/7/25 ABIO